Ardea Remains Neutral

Zacks.com submits: We are maintaining our Neutral recommendation on Allos Therapeutics Inc. (ALTH) with a target price of $3.25.

By Robert Broens: Shares of Ardea Biosciences (RDEA) closed the first trading day of the week 52% higher closing at $31.62 after AstraZeneca PLC announced it has reached an agreement to acquire the company. The deal

By Thomas Meyer:Celldex Therapeutics (CLDX) is up more than 25% on the day due to positive Phase II results in their CDX-011 trials to treat breast cancer. (click to enlarge) Company Profile

Zacks.com submits: We are maintaining our Neutral recommendation on Southwestern Energy Company (SWN) with a target price of $40.

Researchers believe that there will be a breakthrough in finding a cure for HIV “within months”. Danish scientists are expecting results that will show that “finding a mass-distributable and affordable cure to HIV is possible”.

Prohost Biotech submits:When the human immunodeficiency virus (HIV) was identified as the cause of the mysterious immune system depletion characterized by horrific vulnerability to infection, multiple dreadful symptoms and ultimately death, the world panicked. The medical and research communities were taken by surprise. Nothing could be said or done to help the agonizing victims or prevent their imminent death.

Prohost Biotech submits: When the human immunodeficiency virus (HIV) was identified as the cause of the mysterious immune system depletion characterized by horrific vulnerability to infection, multiple dreadful symptoms and ultimately death, the world panicked. The medical and research communities were taken by surprise. Nothing could be said or done to help the agonizing victims or prevent their imminent death.

ChinaBio Today submits: Achillion Pharmaceuticals (NSDQ: ACHN) out-licensed the China rights for elvucitabine, to GCA Therapeutics, Ltd. (GCAT) of Jersey City, New Jersey.